A Tribute to Paul Greengard (1925-2019)

Stevin Zorn is President and CEO at MindImmune Therapeutics, Inc., Kingston, RI, USA

1. Paul Greengard: A persistent desire to comprehend the brain, and also to fix it Marc Flajolet, Thu Lan N-Guyen, Vijay Kumar Siripuram and Yashoda Krishna Sunkari 2. Giving names to the actors of synaptic transmission: The long journey from synaptic vesicles to neural plasticity Fabio Benfenati, Martin Bähler and Flavia Valtorta 3. cAMP-regulated phosphoproteins DARPP-32, ARPP16/19, and RCS modulate striatal signal transduction through protein kinases and phosphatases Kyle R. Christensen and Angus C. Nairn 4. DARPP-32 40 years later Jean-Antoine Girault and Angus C. Nairn 5. Effects of nicotine on DARPP-32 and CaMKII signaling relevant to addiction Angela M. Lee and Marina R. Picciotto 6. Modulation of dendritic spines by protein phosphatase-1 Jimcy Platholi and Hugh C. Hemmings Jr 7. Deciphering cell-type specific signal transduction in the brain: Challenges and promises Jean-Pierre Roussarie and Patricia Rodriguez-Rodriguez 8. Drug-activated cells: From immediate early genes to neuronal ensembles in addiction Marine Salery, Arthur Godino and Eric J. Nestler 9. NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranes Francesca Palese, Silvia Pontis, Natalia Realini and Daniele Piomelli 10. Amyloidogenic and anti-amyloidogenic properties of presenilin 1 Victor Bustos, Maria Pulina and Jose Ledo 11. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia Gretchen L Snyder, Kimberly E Vanover, Robert E Davis, Peng Li, Allen Fienberg and Sharon Mates 12. Uniting homeostatic plasticity and exosome biology: A revision of the conceptual framework for drug discovery in neurodegenerative diseases? James K.T. Wang